Novanta Inc. (NASDAQ:NOVT) Q2 2022 Results Earnings Conference Call August 9, 2022 10:00 AM ET Company Participants Ray Nash - Corporate Finance Leader Matthijs Glastra - Chair and Chief Executive Officer Robert Buckley - Chief Financial Officer Conference Call Participants Lee Jagoda - CJS Securities, Inc. Brian Drab - William Blair Robert Mason - Robert W. Baird Andrew Buscaglia - Berenberg Capital Markets Operator Good morning. My name is Andrea and I will be your conference operator today. At this time, ...

Novanta A Trusted Technology Partner June 2022 Safe Harbor Statement The statements in this presentation that relate to guidance, pro forma presentations, future plans, goals, business opportunities, and future events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with business and economic conditions, failure to achieve expected benefits of acquisitions, failure to comply with the Food and Drug Administration regulations, customer and/or suppl ...

Novanta Inc (NASDAQ:NOVT) Q1 2022 Earnings Conference Call May 10, 2022 10:00 AM ET Company Participants Ray Nash - Corporate Finance Leader Matthijs Glastra - CEO & Chairman of the Board Robert Buckley - CFO Conference Call Participants Lee Jagoda - CJS Securities Rob Mason - Baird Brian Drab - William Blair Andrew Buscaglia - Berenberg Operator Good morning. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to the Novanta Inc. 2022 First Quarte ...

Novanta Inc. (NASDAQ:NOVT) Q4 2021 Earnings Conference Call March 1, 2022 10:00 AM ET Company Participants Ray Nash ??? Corporate Finance Leader Matthijs Glastra ??? Chairperson and Chief Executive Officer Robert Buckley ??? Chief Financial Officer Conference Call Participants Lee Jagoda ??? CJS Securities Rob Mason ??? Baird Brian Drab ??? William Blair Andrew Buscaglia ??? Berenberg Operator Good morning. My name is Keith, and I will be your conference operator today. At this time, I would like to welcome ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35083 NOVANTA INC. (Exact name of registrant as specified in its charter) New Brunswick, Canada 98-0110412 (State or other jurisdiction of incorpor ...

Financial Data and Key Metrics Changes - In Q3 2021, Novanta reported approximately $178 million in revenue, representing a 24% year-over-year growth and 15% organic growth, marking the highest single-quarter sales in the company's history [8][10] - Adjusted EBITDA was $40 million, up 34% year-over-year, with an EBITDA margin of nearly 23%, an increase of 160 basis points year-over-year [9][10] - Adjusted diluted earnings per share increased by 79% year-over-year to $0.75 [10][35] Business Line Data and Key Metrics Changes - Medical applications accounted for 53% of total sales, growing 21% year-over-year and 7% sequentially [13][14] - Advanced industrial applications represented 47% of total sales, with a year-over-year growth of 28% and sequential growth of 5% [15] - The Photonics segment experienced a 19% year-over-year revenue increase, while the Precision Motion segment saw a 77% year-over-year growth [39][42] Market Data and Key Metrics Changes - Sales in China grew 28% year-over-year, while sales in Europe and the United States grew 20% and 27% respectively [16] - The overall book-to-bill ratio was 1.32, indicating strong demand across all segments [11] Company Strategy and Development Direction - The company closed the ATI and IMS acquisitions, which are expected to enhance its strategic positioning in high-growth markets [7][23] - Novanta's growth strategy includes expanding into new markets such as arthroscopy pumps and increasing R&D resources to capitalize on design wins [17][18] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing supply chain challenges but expressed confidence in the company's ability to meet customer demand and maintain strong performance [12][26] - The company raised its guidance for the year, indicating optimism about long-term growth in both medical and industrial applications [26][45] Other Important Information - The company experienced a significant factory disruption at its Taunton facility, which impacted production and gross margins [29][31] - Despite supply chain issues, the company reported a healthy vitality index, with new product sales accounting for over 25% of total sales [19] Q&A Session Summary Question: Impact of the Taunton facility issue on revenue - The impact on organic growth was in the mid-single-digit range, approximately 4% to 7% [63] Question: Future gross margin expectations for the Photonics segment - Gross margins in Photonics are expected to remain flat in Q4 due to higher expenses associated with production [64] Question: Growth expectations for the ATI and IMS acquisitions - The ATI business is expected to grow mid- to high single digits, while IMS is anticipated to grow at a mid-single-digit rate [69][71] Question: DNA sequencing business outlook - The DNA sequencing business is expected to catch up to pre-pandemic levels, with strong growth driven by research lab reopenings and COVID variant sequencing [78][81] Question: Surgical market recovery expectations - Customers in the surgical market expect gradual recovery, with hospitals improving their handling of COVID cases and addressing patient backlogs [85]

| --- | --- | --- | |---------------------------------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | A Trusted Technology Partner in Healthcare and Advanced Industrial Markets September 2021 | | | Safe Harbor Statement The statements in this presentation that relate to guidance, pro forma presentations, future plans, goals, business opportunities, and future events or performance are forward-looking statements that involve risks and uncertainties, inc ...

Novanta, Inc. (NASDAQ:NOVT) Q2 2021 Earnings Conference Call August 10, 2021 10:00 AM ET Company Participants Ray Nash - Corporate Finance Leader Matthijs Glastra - Chief Executive Officer Robert Buckley - Chief Financial Officer Conference Call Participants Lee Jagoda - CJS Securities Rob Mason - Baird Brian Drab - William Blair Operator Good morning. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to the Novanta Inc. 2021 Second Quarter Earni ...

| --- | --- | |-------|-------| | | | | | | Safe Harbor Statement The statements in this presentation that relate to guidance, pro forma presentations, future plans, goals, business opportunities, and future events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with business and economic conditions, failure to achieve expected benefits of acquisitions, failure to comply with the Food and Drug Administration regulations, customer and/or supplier ...

Novanta Inc. (NASDAQ:NOVT) Q1 2021 Earnings Conference Call May 11, 2021 10:00 AM ET Corporate Participants Ray Nash - Investor Relations Matthijs Glastra - Chief Executive Officer Robert Buckley - Chief Financial Officer Conference Call Participants Lee Jagoda - CJS Securities Richard Eastman - Robert W. Baird Brian Drab - William Blair Operator Good morning everyone. My name is Jimmy and I will be your conference operator today. At this time, I would like to welcome everyone to the Novanta Incorporated Fi ...